MAESTRIA

Machine Learning Artificial Intelligence Early Detection STroke Atrial Fibrillation.

The MAESTRIA study is an international, multi-centre, non-interventional, observational registry. The main goal is to enrol a representative group of European patients diagnosed with Atrial Fibrillation (AF) to analyse clinical and relevant parameters (digitalised ECG, echocardiograms, cardiac CTs, MRIs and blood biomarkers) that could be used during clinical practise for the diagnosis of atrial cardiomyopathy. The AF patients will be distributed in 3 groups according to the different manifestation of AF: paroxysmal, persistent and permanent AF.

Patients with paroxysmal AF, persistent AF or permanent AF.

Patients (or legally acceptable representative if applicable to country specific regulations) provide written informed consent to participate in the study. The patient has the option to give separate consent to donate extra volume of blood during the routine blood collection, that can be used for biomedical research.

Patient is at least 18 years old.

Patient must own a smartphone with Apple iOS version 14.5 (or higher) or with Android version 8.0 (or higher).

Any disease that limits life expectancy to less than 1 year.

All persons unable to provide informed consent.

All persons exempt from participation in a study or trial by law.

Any medical or psychiatric condition which, in the investigator´s opinion, would preclude the participant from adhering to the protocol or completing the study per protocol.

The MAESTRIA project aims to develop and validate the first integrative diagnostic digital platform for atrial cardiomyopathy diagnosis. This platform will be designed to provide support for improved diagnostic accuracy that increases effectiveness and efficiency of treatments, as well as prevention of the complications of atrial cardiomyopathy, such as atrial fibrillation and stroke.

AFNET is responsible of the development of a novel specific prospective cohort (MAESTRIA-AFNET 10) which will include approximately 600 patients with different clinical manifestation of Atrial Fibrillation (AF): paroxysmal, persistent and permanent AF. 

%
%

Paderborn

Sorbonne University, Paris, France

LEADER of WORKPACKAGE 4 of MAESTRIA (MAESTRIA – AFNET 10): AFNET